Ally Financial Inc. Invests $1.05 Million in Boston Scientific Corporation $BSX

Ally Financial Inc. purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the fourth quarter, HoldingsChannel reports. The firm purchased 11,000 shares of the medical equipment provider’s stock, valued at approximately $1,049,000.

Several other hedge funds have also recently bought and sold shares of BSX. Norges Bank acquired a new position in Boston Scientific during the 4th quarter worth about $2,199,395,000. Egerton Capital UK LLP lifted its stake in Boston Scientific by 223.7% during the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after acquiring an additional 3,671,548 shares in the last quarter. Maverick Capital Ltd. acquired a new position in Boston Scientific during the 4th quarter worth about $280,735,000. Alphinity Investment Management Pty Ltd acquired a new position in Boston Scientific during the 4th quarter worth about $252,918,000. Finally, Marshall Wace LLP lifted its stake in Boston Scientific by 30.7% during the 3rd quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock worth $956,680,000 after acquiring an additional 2,301,383 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts remain constructive on Boston Scientific, with one note saying the stock could still rise sharply from current levels despite this year’s de-rating. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Positive Sentiment: Boston Scientific may benefit from Penumbra’s newly FDA-cleared stroke thrombectomy platform, which one analyst said could add about $100 million in incremental revenue over time. Penumbra’s FDA nod for clot removal tech a win for Boston Scientific
• Positive Sentiment: BTIG stayed bullish on BSX, pointing to valuation and substantial upside potential despite the recent decline in the share price. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
• Positive Sentiment: Boston Scientific reported strong catheter study results, which could support confidence in its clinical pipeline and product adoption. Boston Scientific Corp (BSX) Reports Strong Success Rates From Catheter Study
• Neutral Sentiment: Erste Group trimmed its FY2026 and FY2027 EPS estimates slightly, a modest negative on expectations but not a major change to the broader consensus. Boston Scientific Corporation (NYSE:BSX) – Free Report
• Negative Sentiment: Boston Scientific has repeatedly walked back full-year 2026 guidance, and that ongoing uncertainty is pressuring the stock and contributing to its decline. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Negative Sentiment: One Seeking Alpha piece argues the market is treating BSX like a “broken compounder,” reflecting skepticism that has weighed on the shares. Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One

Analysts Set New Price Targets

BSX has been the topic of several research reports. Oppenheimer set a $90.00 target price on Boston Scientific in a research note on Thursday, April 23rd. Weiss Ratings lowered Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Raymond James Financial reaffirmed an “outperform” rating and issued a $88.00 price target (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. BTIG Research reduced their price target on Boston Scientific from $80.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, June 2nd. Finally, Mizuho reduced their price target on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a research report on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.08.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $46.83 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a fifty-two week low of $45.99 and a fifty-two week high of $109.50. The firm has a market capitalization of $69.60 billion, a PE ratio of 19.59, a price-to-earnings-growth ratio of 0.88 and a beta of 0.56. The stock’s 50-day simple moving average is $56.37 and its 200-day simple moving average is $74.95.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same quarter last year, the company earned $0.75 EPS. The business’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific declared that its board has initiated a share repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling

In other news, Director Cheryl Pegus purchased 1,770 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. This represents a ? increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David C. Habiger purchased 2,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the purchase, the director directly owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 9,800 shares of company stock worth $554,012 in the last quarter. 0.34% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.